相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Natural History of Adult Crohn's Disease in Population-Based Cohorts
Laurent Peyrin-Biroulet et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data
Stefan Schreiber et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee
Asher Kornbluth et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease
Filip Baert et al.
GASTROENTEROLOGY (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Management of Crohn's Disease in Adults
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2009)
Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection
Miguel Regueiro et al.
GASTROENTEROLOGY (2009)
Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
William J. Sandborn et al.
GASTROENTEROLOGY (2009)
Positioning Biologic Agents in the Treatment of Crohn's Disease
Stephen B. Hanauer
INFLAMMATORY BOWEL DISEASES (2009)
Mucosal Healing Predicts Long-term Outcome of Maintenance Therapy with Infliximab in Crohn's Disease
Fabian Schnitzler et al.
INFLAMMATORY BOWEL DISEASES (2009)
Increased Efficacy of Delayed-Release Mesalamine 4.8g/D (800mg Tablet) in Patients Previously Diagnosed with Ulcerative Colitis (UC)
William J. Sandborn et al.
GASTROENTEROLOGY (2009)
Evolving concepts in treatment and disease modification in ulcerative colitis
S. B. Hanauer
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Increased Immune Reactivity Predicts Aggressive Complicating Crohn's Disease in Children
Marla C. Dubinsky et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Cyclosporine and Infliximab as Rescue Therapy for Each Other in Patients With Steroid-Refractory Ulcerative Colitis
Elana A. Maser et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease
Johan Van Limbergent et al.
GASTROENTEROLOGY (2008)
Risk factors for opportunistic infections in patients with inflammatory bowel disease
Murat Toruner et al.
GASTROENTEROLOGY (2008)
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease:: an open randomised trial
Geert D'Haens et al.
LANCET (2008)
Exposing the weaknesses: A systematic review of azathioprine efficacy in ulcerative colitis
Yvette Leung et al.
DIGESTIVE DISEASES AND SCIENCES (2008)
Clinical course in Crohn's disease: Results of a Norwegian population-based ten-year follow-up study
Inger Camilla Solberg et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission
W. J. Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: A cohort study
Roopali Bansal Gupta et al.
GASTROENTEROLOGY (2007)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis
C. W. Lees et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort
Kathrine Frey Froslie et al.
GASTROENTEROLOGY (2007)
Certolizumab pegol for the treatment of Crohn's disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Maintenance therapy with certolizumab pegol for Crohn's disease
Stefan Schreiber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients
Brian G. Feagan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Review article: the burden of hepatic encephalopathy
F. F. Poordad
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Response to corticosteroids in severe ulcerative colitis: A systematic review of the literature and a meta-regression
Dan Turner et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis
Gary R. Lichtenstein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis
Michael A. Kamm et al.
GASTROENTEROLOGY (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Elana A. Maser et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis
David N. Moskovitz et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: A meta-analysis
MT Osterman et al.
GASTROENTEROLOGY (2006)
Oratory markers in IBD: Magic, or unneccessary toys?
S Vermeire et al.
GUT (2006)
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease
P Rutgeerts et al.
GASTROINTESTINAL ENDOSCOPY (2006)
Predictors of Crohn's disease
L Beaugerie et al.
GASTROENTEROLOGY (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
Serum immune responses predict rapid disease progression among children with Crohn's disease: Immune responses predict disease progression
MC Dubinsky et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis
S Ardizzone et al.
GUT (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study
P Marteau et al.
GUT (2005)
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis:: A randomized, placebo-controlled study
G Järnerot et al.
GASTROENTEROLOGY (2005)
Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?
PDR Higgins et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Ciclosporin use in acute ulcerative colitis: a long-term experience
S Campbell et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2005)
Oral Pentasa in the Treatment of Active Crohn's Disease: A Meta-Analysis of Double-Blind, Placebo-Controlled Trials
Stephen B. Hanauer et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis
M Rutter et al.
GASTROENTEROLOGY (2004)
Infliximab for acute, not steroid-refractory ulcerative colitis:: a randomized pilot study
T Ochsenkühn et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2004)
Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis
G Van Assche et al.
GASTROENTEROLOGY (2003)
Inflammatory bowel disease in early childhood and adolescence: special considerations
P Mamula et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2003)
Review article: Mild to moderate Crohn's disease - defining the basis for a new treatment algorithm
WJ Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Medication Nonadherence and the outcomes of patients with quiescent ulcerative colitis
S Kane et al.
AMERICAN JOURNAL OF MEDICINE (2003)
Systematic review: the effectiveness of budesonide therapy for Crohn's disease
SV Kane et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2002)
Long-term evolution of disease behavior of Crohn's disease
J Cosnes et al.
INFLAMMATORY BOWEL DISEASES (2002)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease
MC Dubinsky et al.
GASTROENTEROLOGY (2002)
The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study
WA Faubion et al.
GASTROENTEROLOGY (2001)
Impact of cessation of smoking on the course of ulcerative colitis
L Beaugerie et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2001)
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study
BE Sands et al.
INFLAMMATORY BOWEL DISEASES (2001)
Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease
JA Tibble et al.
GASTROENTEROLOGY (2000)
分享论文
